Preclinical Development of Selective YTHDF2 Binders for AML Treatment

Research unit

INNOSUISSE

Project number

133.757 IP-LS

Project title

Preclinical Development of Selective YTHDF2 Binders for AML Treatment

Texts for this project

	German	French	Italian	English
Key words	-	-	-
Abstract	-	-	-

Category	Text
Key words (English)	Life sciences, Pharmaceuticals
Abstract (English)	The main goal is to found a spin-off as a platform for developing selective binders targeting YTHDF2, a key RNA-binding protein involved in acute myeloid leukemia. We aim to leverage our generative AI technology for developing a strong preclinical candidate and bring it toward commercialization.